Biotech Mailbag: Who Will Run FDA? (TheStreet.com)
The FDA is in turmoil. Morale is low, resources are scarce and too many drug approvals have been delayed at best, or at worst, have become politicized. A look at some options to run the agency in the Obama administration.

Rivaroxaban Phase II Dose-Ranging Study Demonstrates Encouraging Response Rates in Treatment of Acute Coronary ... (Centre Daily Times)
Findings from the Phase II ATLAS ACS TIMI 46 study of rivaroxaban, a novel, investigational, oral anticoagulant, were presented today as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008 in New Orleans by C. Michael Gibson, M.D., director of the TIMI Data Coordinating Center, Harvard Medical School. Results from this Phase II study support advancing ...